SHAREHOLDER NOTICE: Marcus & Boxerman Announces an Ongoing Investigation of Zafgen, Inc. & Encourages Investors to Contact th...
November 26 2015 - 8:23PM
Business Wire
Marcus & Boxerman announces that it is investigating claims
of potential misrepresentations by Zafgen, Inc. (“Zafgen” or the
“Company”) (NASDAQ: ZFGN). The investigation will focus on whether
the Company and its officers violated securities laws by issuing
misleading information to investors.
To join this class action lawsuit, please contact Michael
Boxerman, Esquire, of Marcus & Boxerman, at 312-216-2730, or
via email at mboxerman@marcusboxerman.com.
On October 16, 2015, the Company announced that the FDA had
ordered a "partial clinical hold" on the Company's Beloranib
clinical trials following the death of a patient. When the truth
was revealed, shares dropped, causing investors harm.
No class has been certified in the above action. Until a class
is certified, you are not considered represented by an attorney.
You may also choose to do nothing and be an absent class
member.
This press release may be considered Attorney Advertising in
some jurisdictions under the applicable law and ethical rules.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20151126005538/en/
Marcus & BoxermanMichael Boxerman, Esq.,
312-216-2730Facsimile: 312-216-2720mboxerman@marcusboxerman.com
Zafgen (NASDAQ:ZFGN)
Historical Stock Chart
From Apr 2024 to May 2024
Zafgen (NASDAQ:ZFGN)
Historical Stock Chart
From May 2023 to May 2024
Real-Time news about Zafgen Inc (NASDAQ): 0 recent articles
More Zafgen, Inc. (MM) News Articles